Ekso Bionics Holdings, Inc. (EKSO)
Automate Your Wheel Strategy on EKSO
With Tiblio's Option Bot, you can configure your own wheel strategy including EKSO - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol EKSO
- Rev/Share 5.638
- Book/Share 3.6999
- PB 1.1284
- Debt/Equity 0.3118
- CurrentRatio 1.6552
- ROIC -0.7654
- MktCap 10948311.0
- FreeCF/Share -3.3922
- PFCF -1.2338
- PE -1.0468
- Debt/Assets 0.1393
- DivYield 0
- ROE -0.9071
- Rating C+
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 4
- P/B Score 3
- D/E Score 2
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
Ekso Bionics Announces $3.7 Million Registered Direct Offering of Common Stock Priced At-the-Market under Nasdaq Rules
Published: October 29, 2025 by: GlobeNewsWire
Sentiment: Neutral
SAN RAFAEL, Calif., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (the “Company”) (Nasdaq: EKSO), a leading developer of exoskeletons for medical and industrial use, today announced that on October 28, 2025, it entered into a definitive agreement with certain institutional investors for the purchase and sale of an aggregate of 769,490 shares of the Company's common stock at a purchase price of $4.81 per share of common stock in a registered direct offering priced at-the-market under Nasdaq rules.
Read More
Ekso Bionics (EKSO) Upgraded to Buy: Here's What You Should Know
Published: September 26, 2025 by: Zacks Investment Research
Sentiment: Positive
Ekso Bionics (EKSO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Read More
Ekso Bionics (EKSO) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
Published: August 13, 2025 by: Zacks Investment Research
Sentiment: Positive
Ekso Bionics (EKSO) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
Read More
Ekso Bionics to Report Fourth Quarter and Full Year 2024 Financial Results on March 3 – Conference Call to Follow
Published: February 24, 2025 by: GlobeNewsWire
Sentiment: Neutral
SAN RAFAEL, Calif., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today announced that it will release financial and business results for the fourth quarter and full year 2024 after the close of trading on Monday, March 3, 2025. Management will host a conference call beginning at 1:30 p.m. PT / 4:30 p.m. ET to review the financial results and discuss recent business developments.
Read More
NSM Named Exclusive Distributor of Ekso Indego® Personal Within the CRT Industry
Published: February 10, 2025 by: GlobeNewsWire
Sentiment: Neutral
Move expected to broaden access to Ekso Bionics' portable exoskeleton device for individuals living with spinal cord injuries and other mobility challenges across the United States Move expected to broaden access to Ekso Bionics' portable exoskeleton device for individuals living with spinal cord injuries and other mobility challenges across the United States
Read More
About Ekso Bionics Holdings, Inc. (EKSO)
- IPO Date 2014-01-17
- Website https://www.eksobionics.com
- Industry Medical - Instruments & Supplies
- CEO Scott G. Davis
- Employees 61